Thyroid carcinoma is the most frequent endocrine neoplasia. Different types of thyroid
carcinoma are described: well-differentiated papillary thyroid carcinoma (PTC), poorly …

Background Thyroid cancer is the fastest increasing cancer in the US, and papillary thyroid
cancer (PTC) accounts for> 80% of incident cases. Increasing exposure to flame retardant …

Anaplastic thyroid carcinoma (ATC) is the most aggressive form of thyroid cancer. It shows a
wide spectrum of morphological presentations and the diagnosis could be challenging due …

In the 9 years since the publication of our 2011 review of targeted treatment of thyroid cancer
with multikinase inhibitors, much has changed in the landscape of this heterogeneous …

The last decade has seen a renewed interested in a risk-adapted approach to the
management of differentiated thyroid cancer (DTC), in which specific treatment and follow …

Context How lymph node metastasis (LNM)-associated mortality risk is affected by BRAF
V600E in papillary thyroid cancer (PTC) remains undefined. Objective To study whether …

Background. Over the past ten years, the incidence rate of papillary thyroid carcinoma (PTC)
worldwide has been increasing rapidly year by year, with the incidence rate increasing 6 …

The treatment paradigm for thyroid cancer has shifted from a one-size-fits-all approach to
more personalized protocols that range from active surveillance to total thyroidectomy …

The impact of BRAF mutations on the clinical outcomes of PTC remains debatable. In ATCs,
in turn, BRAF mutations identify patients eligible for targeted therapy, which is now …

Introduction The use of molecular markers, especially BRAF and TERT promoter mutations,
for risk stratification in papillary thyroid carcinoma (PTC) is subject to continuing debate. In …